Scott Morenstein is a Managing Director at CAM Capital, a private investment company established by Bruce Kovner for his proprietary investment, trading and business activities. Scott has been a Director of Celator Pharmaceuticals (Nasdaq: CPXX) since 2013 and recently joined the Board of Synta Pharmaceuticals (Nasdaq: SNTA). In addition to Celator, investments while at CAM Capital include: ProNAi Therapeutics (Nasdaq: DNAI), Agile Therapeutics (Nasdaq: AGRX), Cidara Therapeutics (Nasdaq: CDTX), and Blueprint Medicines (Nasdaq: BPMC). Prior to joining CAM Capital, Mr. Morenstein was a Managing Director of Valence Life Sciences and Caxton Advantage Venture Partners, venture capital firms focused on late-stage investing in private and small cap public drug development companies. He was previously a healthcare investment banker and research analyst at Lehman Brothers and Seaview Securities. Mr. Morenstein received a B.A. from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems and an M.B.A. from Harvard Business School.